Table 1.

Incidence of RSVH and hospital resource use in children with BPD and/or history of prematurity (≤ 35 wGA) in the PREVENT trial [53]

	RSV-IGIV (n = 250)	Placebo (n = 260)	Reduction	P value
Incidence of RSVH (%)	8.0	13.5	41%	0.047
Total days of hospitalization per 100 children	60	129	53%	0.045
Total days of RSVH requiring increased supplemental oxygen per 100 children	34	85	60%	0.007
Number of hospital days with moderate or severe LRI (LRI score ≥ 3a) per 100 children	49	106	54%	0.049
Total days of ICU or mechanical ventilation for RSV per 100 children	28	50	–	–

ICU intensive care unit, LRI lower respiratory infection/illness, RSV-IGIV respiratory syncytial virus intravenous immunoglobulin, RSVH respiratory syncytial virus hospitalization

^aLRI score: 0 = no respiratory illness/infection; 1 = upper respiratory tract illness (URI); 2 = mild LRI; 3 = moderate LRI; 4 = severe LRI; 5 = mechanical ventilation. The LRI score was calculated as the mode of the following three (A, B, C) component scores, or the mean if there was no mode: A. Oxygen saturation—0 = Baseline value (no URI), 1 = Baseline value (URI), 2 = Decrease < 5%, 3 = Decrease 5–10%, 4 = Decrease > 10%, 5 = Mechanical ventilation; B. Respiratory rate—0 = Baseline value (no URI), 1 = Baseline value (URI), 2 = Increase 1–14/min, 3 = Increase 15-30/min, 4 = Increase > 30/min, 5 = Mechanical ventilation; C. Retractions, Wheezing, Crackles—0 = No change (no URI), 1 = Minimal, 2 = Mild, 3 = Moderate, 4 = Severe, 5 = Mechanical ventilation [51]. Values for oxygen saturation, respiratory rate, and pulmonary findings were compared with baseline values on usual oxygen flow [51]